For market prepared sleeping pills whose manufacturers promise the absence of any side effects. Moreover, these drugs will treat the cause of insomnia, rather than the consequence.
Most conventional hypnotics focused on brain neurotransmitter GABA (gamma-aminobutyric acid) that causes drowsiness, and DORA-22 (working title, which will soon be replaced by a more sonorous) affects the neuropeptide orexin, which does not allow us to sleep. The drug reduces the activity of orexin, and people gradually put to sleep in a natural way, as if it happened without any drug intervention. The usual pills artificially induce sleep, like surgical anesthesia.
In laboratory tests DORA-22 treated rats slept longer than those rodents, who were given placebo. The next stage tests showed that sleeping pills do not cause problems with memory, were observed in rats treated with Valium or other modern pills against insomnia. These issues were the monkeys who were given conventional sleeping pills, but DORA-22 in their memory is not affected, nor slowed reaction rate even at very high doses.
So far, the drug is still going through a phase of laboratory tests and tests on animals, and its entry into the market is possible only after pill tested on humans. Some experts, however, believe that the creators of DORA-22 must pay attention to other side effects, not on memory and reaction. For example, it is known that exposure of orexin can increase appetite. (READ MORE)
Industry News
Go back to the main page
No comments:
Post a Comment